Prime Medicine, Inc.
PRMENASDAQHealthcare● Active
$2.97
$-0.09(-2.94%)
Market Cap$536433827
P/E Ratio—
52W High$6.94
52W Low$1.305
Prime Medicine, Inc. (PRME) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRME · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.28
Est. -$0.24 · -16.7%
Revenue
$0.00B
Est. $0.00B · -63.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
PRME reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.24 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.24 | -$0.28 | -16.7% | $0.00B | $0.00B | -63.2% |
| ▲ Q1 FY2026 | Mar 3, 2026 | -$0.25 | -$0.22 | +12.0% | $0.00B | $0.00B | -34.6% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.28 | -$0.32 | -14.3% | $0.00B | $0.00B | -40.3% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.36 | -$0.41 | -13.9% | $0.00B | $0.00B | -60.2% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.32 | -$0.40 | -25.0% | $0.00B | $0.00B | -37.7% |
| ▲ Q1 FY2025 | Feb 28, 2025 | -$0.37 | -$0.31 | +16.2% | $0.00B | $0.01B | -67.8% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.43 | -$0.44 | -2.3% | $0.00B | $0.01B | -97.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.28
EPS Est.
-$0.24
EPS Surpr.
-16.7%
Revenue
$0.00B
Q1 FY2026
Mar 3, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.25
EPS Surpr.
+12.0%
Revenue
$0.00B
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.28
EPS Surpr.
-14.3%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.36
EPS Surpr.
-13.9%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.32
EPS Surpr.
-25.0%
Revenue
$0.00B
Q1 FY2025
Feb 28, 2025Beat
EPS Actual
-$0.31
EPS Est.
-$0.37
EPS Surpr.
+16.2%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.44
EPS Est.
-$0.43
EPS Surpr.
-2.3%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.78 | $-0.21 | $0.02 | 4 |
| Q3 FY2028 | $-0.78 | $-0.21 | $0.02 | 6 |
| Q2 FY2028 | $-0.79 | $-0.21 | $0.02 | 4 |
| Q1 FY2028 | $-0.78 | $-0.21 | $0.02 | 4 |
| Q4 FY2027 | $-1.11 | $-0.29 | $0.03 | 3 |
| Q3 FY2027 | $-1.07 | $-0.28 | $0.03 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -16.7% | $3.41 | $3.12 | -8.50% |
| ▲ Q1 FY2026 | Mar 3, 2026 | +12.0% | $4.66 | $4.23 | -9.23% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -14.3% | $4.18 | $3.81 | -8.85% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -13.9% | $4.07 | $3.68 | -9.58% |
| ▼ Q2 FY2025 | May 8, 2025 | -25.0% | $1.42 | $1.32 | -7.04% |
| ▲ Q1 FY2025 | Feb 28, 2025 | +16.2% | $2.42 | $2.52 | +4.13% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -2.3% | $4.39 | $4.32 | -1.59% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -15.0% | $4.40 | $4.39 | -0.23% |
Q2 FY2026-8.50%
Report Date
May 7, 2026
EPS Beat/Miss
-16.7%
Price Before
$3.41
Price After
$3.12
Q1 FY2026-9.23%
Report Date
Mar 3, 2026
EPS Beat/Miss
+12.0%
Price Before
$4.66
Price After
$4.23
Q4 FY2025-8.85%
Report Date
Nov 7, 2025
EPS Beat/Miss
-14.3%
Price Before
$4.18
Price After
$3.81
Q3 FY2025-9.58%
Report Date
Aug 7, 2025
EPS Beat/Miss
-13.9%
Price Before
$4.07
Price After
$3.68
Q2 FY2025-7.04%
Report Date
May 8, 2025
EPS Beat/Miss
-25.0%
Price Before
$1.42
Price After
$1.32
Q1 FY2025+4.13%
Report Date
Feb 28, 2025
EPS Beat/Miss
+16.2%
Price Before
$2.42
Price After
$2.52
Q4 FY2024-1.59%
Report Date
Nov 12, 2024
EPS Beat/Miss
-2.3%
Price Before
$4.39
Price After
$4.32
Q3 FY2024-0.23%
Report Date
Aug 8, 2024
EPS Beat/Miss
-15.0%
Price Before
$4.40
Price After
$4.39
Avg Beat Reaction-2.55%
Avg Miss Reaction-5.96%
Beat Rate2 / 8 quarters
Largest Move-9.58% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRME ends December
Prime Medicine, Inc. (PRME) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.28 — missing the analyst consensus of $-0.24 by -16.7%. The next PRME earnings date is expected around September 1, 2026.
Each quarter, investors track PRME earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRME revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRME's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRME earnings · 5 questionsPrime Medicine, Inc.'s next earnings report is expected around September 1, 2026. PRME typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRME historically reports after market close (AMC).
PRME earnings datewhen is PRME earningsPRME next earnings datewhen does PRME report earningsPRME earnings calendar
▸ Source: FMP · Prime Medicine, Inc. SEC filings · US GAAP · Prime Medicine, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026